Korea / KHIDI President Talks Domestic Vaccine R&D
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Korea Health Industry Development Institute (KHIDI) is a government-affiliated institution which performs professional and systematic support to develop domestic health industry and enhance health services.
Since its establishment in 1999, KHIDI has led expansion of healthcare R&D investment and building competitiveness of Korea’s healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. We are also witnessing rapid growth of global healthcare sector – especially in attracting foreign patients and exporting healthcare service providers along with healthcare systems. This is a valuable outcome we have earned through years of efforts on global advancement and outreach in this sector.Since its establishment in 1999, KHIDI has been playing a major role in the industry development as the nation’s only one organization responsible for fostering health industry. While we have striven to produce more successful research outcomes by means of greater investments in Health Technology (HT) R&D, KHIDI also took the initiative in increasing competitiveness in different areas of health industry, including pharmaceuticals, medical devices, foods, and beauty & cosmetics businesses.
Contact details:
Address: 187 Osongsaengmyeong2(i)-ro, Gangoe-myeon, Cheongwon-gun, Chungcheongbuk-do, 363-951 Korea
Tel: +82-43-713-8000 ~ 8005
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Dr Jino Park, founder and CEO of P&K Skin Research Centre, offers his assessment of the success of the Korean pharmaceutical industry, and the potential cosmetic products of the future.…
Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its…
* This interview was conducted before GE’s announcement of its divestment of the GE Biopharma business Francis Van Parys, president & CEO of GE Healthcare Korea discusses their ambitions to…
Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country…
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s…
Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of…
Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision…
Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits…
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical…
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a…
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing…
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
See our Cookie Privacy Policy Here